BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said it has filed a PCT patent application along with a US application for lysergic acid diethylamide (LSD) derivatives, including 2-bromo-LSD.
The applications cover compositions of these derivatives for use in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and pain, according to BetterLife.
BetterLife said it is developing a new composition of 2-bromo-LSD, BETR-001, covered by these patent filings. BETR-001 is a second-generation LSD derivative molecule that does not cause hallucinations, and therefore is not subject to global controlled substance regulations.
READ: BetterLife Pharma and collaborators to submit key joint research on BETR-001 to publication
In addition, the synthesis of BETR-001 is via non-controlled substance synthetic routes, and therefore not subject to controlled substance regulatory restrictions.
Vancouver-based BetterLife is already in advanced stages of good manufacturing practices (GMP) of BETR-001 and completing the necessary pre-clinical IND-enabling studies for BETR-001. BetterLife said it expects to file the BETR-001 IND and start phase 1 in healthy subjects in the first half of 2023.
"The inventions covered by the patent filings are comprehensive and involve significant body of data including composition of matter, pre-clinical in-vitro and in-vivo characterization of BETR-001 that will be submitted for publication in a prestigious peer-reviewed journal, in the near future,” BetterLife CEO Ahmad Doroudian said in a statement.
“Based on the data generated to date, we believe BETR-001 holds great promise in becoming a major treatment for a range of mental health and neurological conditions, including depression, anxiety, pain and related disorders," he added.
BetterLife Pharma is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.
Contact the author at susie@proactiveinvestors.com